Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National.

Slides:



Advertisements
Similar presentations
The National Kidney Foundations Kidney Early Evaluation Program TM The National Kidney Foundations Kidney Early Evaluation Program TM Essex-Passaic Wellness.
Advertisements

+ Understanding Kidney Disease and Renal Dialysis Brooke Grussing Concordia College.
Diabetes, Anemia and Chronic Kidney Disease Josephine Carlos-Raboca,M.D., F.P.S.E.M., Endocrinology, Diabetes and Metabolism Makati Medical Center.
Chronic Kidney Disease Manju Sood GPST3. What is CKD? Chronic renal failure is the progressive loss of nephrons resulting in permanent compromise of renal.
Mayrene Hernandez, DO Advanced ProMed Inc. Billing and Management Solutions Board Certified in Family Medicine Clinical Assistant Professor for NSU.
Prepared by D. Chaplin Chronic Renal Failure. Prepared by D. Chaplin Chronic Renal Failure Progressive, irreversible damage to the nephrons and glomeruli.
Chronic Kidney Disease/Dialysis Belinda Jim, MD January 15, 2009.
Chronic kidney disease: [insert title here] Insert name, title, date here Insert acknowledgements here.
Recent Advances in Management of CRF Yousef Boobess, M.D. Head, Nephrology Division Tawam Hospital.
SLOW- COOKING THE BEANS “OR, HOW TO STOP WORRYING AND APPLY SOME LOVE TO THE KIDNEYS” AN APPROACH TO CKD SARA KATE LEVIN, MD JANUARY 2014.
General Practice Workshop This workshop was conceived and developed by Kidney Health Australia’s Kidney Check Australia Taskforce with particular thanks.
CKD In Primary Care Dr Mohammed Javid.
National Institute for Health and Clinical Excellence.
Chapter 1: CKD in the General Population 2014 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
Chronic Kidney Disease Workshop Maarten Taal Department of Renal Medicine Derby City General Hospital Derby Nephrology Research.
Mugendi AG, BPharm, MPharm (Clin Pharm). Comparison of the effects of losartan and enalapril on renal function in adults with chronic kidney disease at.
Lesley Stevens MD Tufts-New England Medical Center
Chronic Kidney Disease (CKD)
BY: DR. NAUSHAD PERVEZ.  Chronic Kidney Disease (CKD)
Section 1: CKD Epidemiology. The Problem Chronic Kidney Disease is an epidemic worldwide –Growth 6-8% per annum of dialysis patients Accumulating data.
Estimated GFR Based on Creatinine and Cystatin C
This lecture was conducted during the Nephrology Unit Grand Ground by a Sub-intern under Nephrology Division, Department of Medicine in King Saud University.
CHRONIC RENAL FAILURE JAKUB ZÁVADA KLINIKA NEFROLOGIE 1.LF UK.
Health Care Costs Associated with Chronic Kidney Disease in Patients with Type II Diabetes Zita Shiue, MD Internal Medicine, R3 Chief of Medicine Conference.
6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
The National Kidney Foundation’s Kidney Early Evaluation Program TM “The Greater New York Experience” Ellen H. Yoshiuchi, MPS Division Program Director.
CASE 1. Donald is a 68 year-old man who is admitted to hospital via the Emergency Department one day, following a myocardial infarction. Subsequent investigation.
Section 6: Management in primary care Particular emphasis on nurse practitioner’s role.
If I had Chronic Kidney Disease: What would I want my Doctor to Know….. Liam Plant Department of Renal Medicine, Cork University Hospital Department of.
SHEFFIELD GUIDELINES: RENAL DISEASE IN DIABETES Dr Jenny Stephenson GP, Stannington Medical Centre
The management of renal problems in primary care Hugh Gallagher Consultant Nephrologist St Helier Hospital.
Diabetic Nephropathy.  Over 40% of new cases of end-stage renal disease (ESRD) are attributed to diabetes.  In 2001, 41,312 people with diabetes began.
Evaluation of Renal Function. Normal volumes and composition of electrolytes in various body fluid compartments are essential for maintenance of life.
Section 5: Configuration of healthcare to manage CKD.
Section 3: CKD, CVD and mortality. Cardiovascular diseases in CKD patients Damage to the heart (Uraemic cardiomyopathy ) Damage to the arteries (Uraemic.
Dr M Sivalingam Renal Unit, Lister Hospital, Stevenage.
Renal Disease Normal Anatomy andPhysiology. Renal: Normal Anatomy 1. Renal artery and vein: 25% of blood volume passes through the kidney / minute 2.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Chapter 1: CKD in the General Population 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
Chronic Kidney Disease: Treatment. Slowing the Progression of CKD Protein Restriction – KDOQI guidelines g/kg per day – Sufficient energy.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Chronic renal failure and common accompanying diseases Hradec Králové, November 2007 © by Adrian Franke.
Chapter 37 Chronic Kidney Disease: The New Epidemic
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Lab (5): Renal Function test (RFT) (Part 2) T.A Nouf Alshareef T.A Bahiya Osrah KAU-Faculty of Science- Biochemistry department Clinical biochemistry lab.
Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.
Hot Topics Clinical Dr Sian Stanley. Why Hot topics? GPs love them. Recurring theme throughout GP training. Who decides what’s hot and what’s not? Clinically.
Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive.
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated.
Kidney Disease Healthy Christian Presentation May 25, 2016.
Section 1: CKD Epidemiology
Figure 1.1 Prevalence of CKD by stage among NHANES participants,
Section 6: Management in primary care
Darshika Chhabra, MD, MPH
Care of the Renal Failure Patient
2017 Annual Data Report Healthy People 2020.
Chapter 1: CKD in the General Population
The MDRD Study.
Acute and Chronic Renal Failure
Renal Disease Filtration, glomeruli generate removal ultrafiltrate of the plasma based on size and charge of molecules End products include urea, creatinine,
Chronic Kidney Disease in HIV Infection: An Urban Epidemic
2018 Annual Data Report Volume 3: Healthy People 2020
Chapter 1: CKD in the General Population
Section 5: Configuration of healthcare to manage CKD
Meeting the challenges of the new K/DOQI guidelines
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Chronic Kidney Disease
American Journal of Kidney Diseases
Lesley A. Stevens, MD, MS, Josef Coresh, MD, PhD, Andrew S. Levey, MD 
Presentation transcript:

Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National Kidney Foundation data 1/29/2009) disease (CKD) ( National Kidney Foundation data 1/29/2009) The awareness of Kidney Disease The awareness of Kidney Disease It is estimated that million people unaware It is estimated that million people unaware they have CKD (National Institute of Diabetes and Digestive Kidney Disease data summer 2010 ) they have CKD (National Institute of Diabetes and Digestive Kidney Disease data summer 2010 ) Cause of this problem: Reliance Cause of this problem: Reliance of many primary medical providers on the serum of many primary medical providers on the serum creatinine alone. eGFR more accurate creatinine alone. eGFR more accurate estimate. estimate.

Prevalance continued eGFR is calculated by the MDRD equation eGFR is calculated by the MDRD equation which uses age, weight, gender and which uses age, weight, gender and serum creatinine serum creatinine Levey AS, Bosch JP, Lewis JB et all: (ann Intern Med (6): Levey AS, Bosch JP, Lewis JB et all: (ann Intern Med (6): Example: 70 yoF with creatinine of 1.2 Example: 70 yoF with creatinine of 1.2 has GFR of 45ml/min; has GFR of 45ml/min; a 20 yo M with same creatinine has GFR a 20 yo M with same creatinine has GFR of >100ml/min of >100ml/min

Prevalance of CKD in Older Population Prevalance of CKD in Older Population NHANES analysis NHANES analysis Those age 65 + have 44.7% CKD Those age 65 + have 44.7% CKD Of these 54.6% have diabetes Of these 54.6% have diabetes The 33.1% of non diabetic The 33.1% of non diabetic population has CKD population has CKD Of those in age group Of those in age group 43.8% have CKD 43.8% have CKD ( 2008 USRDS Annual Data Report) ( 2008 USRDS Annual Data Report)

Functions of the kidneys Red blood cell production via erythropoeitin Red blood cell production via erythropoeitin Hypertension control through the renin Hypertension control through the renin angiotension hormonal regulation of salt angiotension hormonal regulation of salt balance and vasoconstriction balance and vasoconstriction PTH regulation of calcium and phosphorus PTH regulation of calcium and phosphorus metabolism metabolism Waste and fluid filtration Waste and fluid filtration Electrolyte balance Electrolyte balance

StagesDescriptionGFRTreatment 1 Kidney damage with normal GFR or hyperfiltration >90 >90 Identify risk of progressive renal disease. Monitor regularly, treat HTN. 2 Kidney damage with mild decrease in GFR Identify risk of progressive renal disease. Monitor regularly, treat HTN 3 Moderate decrease in GFR Proteinuria Hypertension Refer if GFR declines>25%/yr Consider ACEI ARB 4 Severe decrease in GFR PTH, calcium, hgb and HTN 5 Kidney failure <15 (or dialysis) Dialysis/or transplant

Treatment by stages Stage 1 and 2 if proteinuria present Stage 1 and 2 if proteinuria present Evaluate for risk of progression Manage hypertension if present Stage 3 Stage 3 Use of angiotension converting enzyme inhibitors to control hypertension and proteinuria, Use of angiotension converting enzyme inhibitors to control hypertension and proteinuria, Identify and treat anemia and hyperparathyroidism, Identify and treat anemia and hyperparathyroidism, Decrease medication doses as appropriate, adjust insulin dose, Educate on meal planning Decrease medication doses as appropriate, adjust insulin dose, Educate on meal planning Appointments every 3-4 months with lab testing Appointments every 3-4 months with lab testing Begin education regarding end stage Begin education regarding end stage

Stages continued Stage 4 Stage 4 Same medical management as in stage 3 Same medical management as in stage 3 Appointments every month with lab testing as GFR declines Appointments every month with lab testing as GFR declines Appointment to discuss end stage renal disease treatment options in Appointment to discuss end stage renal disease treatment options in detail with patient and family; access placement for dialysis; initiate transplant workup if patient is a candidate detail with patient and family; access placement for dialysis; initiate transplant workup if patient is a candidate Manage fluid status; need ongoing evaluation Manage fluid status; need ongoing evaluation of edema of edema Stage 5 Initiate dialysis or transplant Stage 5 Initiate dialysis or transplant Close monitoring of weights, evaluation of edema, and potassium, Close monitoring of weights, evaluation of edema, and potassium, and phosphorus consumption and phosphorus consumption

Treatment considerations by stage for insulin and oral agent use StageGFR Insulin or oral agent 1 & 2 1 & 2 Greater than 90 Usual management 3 60 – 90 May have lower medication dose requirement Same as in stage May require higher medication dose requirement